secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K/A
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0000950170-24-039634
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa reports FY2023 results: $88.5M cash, R&D spend up; two Phase 2 trials fully enrolled
--------------------------------------------------------------------------------

- Ended FY2023 with $88.5M cash and equivalents, no debt.
- Total operating expenses were $31.4M, up from $27.7M in FY2022, driven by higher R&D and G&A.
- Two Phase 2 trials fully enrolled (Karisma-Endoxifen and I-SPY2); top-line data awaited H2 2024.
- Recorded $3.0M impairment charge on investment in DCT; interest income rose to $4.3M from $0.9M.
- Data from EVANGELINE Phase 2 study to be presented at AACR Annual Meeting on April 9, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024039634/0000950170-24-039634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024039634/atos-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer